Education
About Us
Working with TipRanks
Follow Us
Moderna (MRNA)
NASDAQ:MRNA
MRNA Stock Chart & Stats
$41.95
-$4.21(-8.86%)
At close: 4:00 PM EST
$41.95
-$4.21(-8.86%)
Day’s Range― - ―
52-Week Range$22.28 - $55.20
Previous CloseN/A
Volume7.58M
Average Volume (3M)12.36M
Market Cap
$16.41B
Enterprise Value$14.99B
Total Cash (Recent Filing)$4.50B
Total Debt (Recent Filing)$734.00M
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Feb 13, 2026EPS Estimate
-2.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding390,733,640
10 Day Avg. Volume10,899,191
30 Day Avg. Volume12,363,293
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)1.46
Price to Sales (P/S)4.99
P/FCF Ratio-3.94
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue6.75
Enterprise Value/Gross Profit56.58
Enterprise Value/Ebitda-5.10
Forecast
1Y Price Target
$31.19Price Target Upside-25.65% Downside
Rating ConsensusHold
Number of Analyst Covering20
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial Partnership TermsThe partnership with Recordati transfers commercialization responsibilities and provides upfront and milestone payments, which reduces internal launch costs and supports cash flow predictability.
International Regulatory ProgressAcceptance of seasonal vaccine applications for review in the EU, Canada, and Australia opens multiple non‑U.S. approval pathways that could expand market access and diversify revenue sources.
Patent Litigation DefenseCourt rulings that rejected broad equivalence arguments and narrowed alternative infringement theories bolster the company's defense on formulation patents and lower potential legal exposure for those claims.
Bears Say
Financial And Valuation ImpactAnalyst models removing the vaccine's U.S. revenue contribution and trimming program spending indicate potential downward pressure on revenue forecasts and valuation assumptions.
Pricing And Reimbursement PressureAnalyst emphasis on relationships with pharmacy benefit managers and health care services signals that pricing and reimbursement dynamics could constrain commercial uptake and limit revenue realization.
Regulatory Setback And Trial RiskAn FDA refusal‑to‑file driven by the choice of comparator raises the possibility of an additional U.S. trial, creating substantial uncertainty around potential U.S. approval and launch timelines.
Moderna News
MRNA FAQ
What was Moderna’s price range in the past 12 months?
Moderna lowest stock price was $22.28 and its highest was $55.20 in the past 12 months.
What is Moderna’s market cap?
Moderna’s market cap is $16.41B.
When is Moderna’s upcoming earnings report date?
Moderna’s upcoming earnings report date is Feb 13, 2026 which is today.
How were Moderna’s earnings last quarter?
Currently, no data Available
Is Moderna overvalued?
According to Wall Street analysts Moderna’s price is currently Overvalued.
Does Moderna pay dividends?
Moderna does not currently pay dividends.
What is Moderna’s EPS estimate?
Moderna’s EPS estimate is -2.54.
How many shares outstanding does Moderna have?
Moderna has 390,733,640 shares outstanding.
What happened to Moderna’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Moderna?
Currently, no hedge funds are holding shares in MRNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Moderna Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$31.19 (-25.65% Downside)
$31.19 (-25.65% Downside)
Blogger Sentiment
Bullish
MRNA Sentiment 84%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 592.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $703.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 15.6%
Last 30 Days ▼ 15.6%
News Sentiment
Very Bearish
Bullish news 15%
Bearish news 85%
Bearish news 85%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.68%
12-Months-Change
Fundamentals
Return on Equity
-29.32%
Trailing 12-Months
Asset Growth
-23.21%
Trailing 12-Months
Company Description
Moderna
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
MRNA Company Deck
MRNA Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant achievements in cost reduction, strategic partnerships, and product approvals. However, these positives were tempered by notable challenges, including a significant revenue decline, a net loss for the quarter, and the discontinuation of the CMV vaccine program.View all MRNA earnings summariesMRNA Revenue Breakdown
55.16% U.S.
18.48% Europe
26.36% Rest of World
MRNA Stock 12 Month Forecast
Average Price Target
$31.19
▼(-25.65% Downside)
Technical Analysis
Ionis Pharmaceuticals
―
Protagonist Therapeutics
―
Rhythm Pharmaceuticals
―
Revolution Medicines
―
―
Ownership Overview
7.94% Insiders
19.16% Mutual Funds
11.15% Other Institutional Investors
36.64% Public Companies and Individual Investors